CRISPR Lateral Flow Diagnostics for Point-of-Care Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid diagnostic methods face challenges in achieving high sensitivity and specificity while being cost-effective and portable, limiting their usability in point-of-care settings for rapid disease detection.
Innovation Solution
A lateral flow device incorporating a CRISPR effector system with a substrate loaded with detectable ligands, CRISPR effector proteins, and guide sequences, which utilizes RNA or DNA targeting capabilities to detect target nucleic acids, enabling sensitive and specific detection of diseases on a portable platform.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qPCR approaches are used for nucleic acid detection, then sensitivity is improved, but cost and device complexity increase, limiting portability
Solution Approach 1:
The patent replaces complex mechanical/qPCR instrumentation with a CRISPR-based biochemical system that uses guide RNA-programmed nucleases to detect target sequences. This substitution eliminates the need for thermal cycling machines and complex optical detection systems, achieving high sensitivity through sequence-specific cleavage followed by simple readout methods
Solution Approach 2:
The invention extracts the essential detection function from complex qPCR instrumentation by isolating the sequence-specific recognition and amplification steps. The CRISPR system extracts only the necessary elements (guide RNA, nuclease, target sequence) to achieve detection, removing unnecessary complex machinery while maintaining sensitivity
2Ease of operation
If isothermal nucleic acid amplification with portable platforms is used, then portability and simplicity are improved, but detection sensitivity decreases
Solution Approach 1:
The patent merges isothermal amplification methods (such as RPA or LAMP) with CRISPR-based detection in a single portable platform. This combination allows the system to maintain the portability and simplicity of isothermal methods while achieving high sensitivity through the specific and efficient target recognition and amplification capabilities of the CRISPR system
Solution Approach 2:
The invention creates a composite diagnostic system that integrates multiple functional components: isothermal amplification reagents, CRISPR guide RNAs, effector proteins, and detection substrates. This composite approach combines the advantages of isothermal amplification (portability, simplicity) with CRISPR detection (high sensitivity, specificity) into a unified portable platform
3Measurement precision
If high sensitivity and specificity are achieved in nucleic acid detection, then diagnostic accuracy is improved, but cost increases
Solution Approach 1:
The patent employs disposable, pre-assembled CRISPR detection cartridges or lateral flow strips that contain guide RNAs, effector proteins, and detection substrates. These single-use devices eliminate the need for expensive, reusable instrumentation while maintaining high detection specificity through the programmable and highly specific nature of CRISPR target recognition
Solution Approach 2:
The invention achieves high specificity at low cost by changing the detection parameter from instrument-based measurement to biochemical reaction-based detection. The CRISPR system's natural high specificity (single-base-pair discrimination) is harnessed through simple readout methods such as colorimetric or fluorescent lateral flow, eliminating expensive instrumentation while maintaining diagnostic accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides attomolar sensitivity for detecting DNA and RNA, differentiating targets based on single base pair differences, and can be used in various applications, including viral and bacterial detection, making it suitable for point-of-care diagnostics.
Implementation Method 1
guide sequences configured to bind to one or more target sequences
Implementation Method 2
a second binding agent that specifically binds the second molecule of the reporter construct
Data Source
AI summary
Provided herein is a lateral flow diagnostic device and methods of using thereof. The device comprises a substrate and a first end, wherein the first end comprises a sample loading portion. The first end may further comprise a first region loaded with a detectable ligand, a CRISPR effector system, a detection construct, a first test band comprising a biotin ligand, and a second test band comprising a capture molecule for the detectable ligand. The detection construct may comprise an RNA oligonucleotide, having a first molecule such as FITC on a first end and a second molecule such as FAM on a second end. Contacting the sample loading portion with a sample causes the sample to flow from the sample loading portion of the substrate towards the first and second capture regions, thereby generating a detectable signal, which may be indicative of a disease state.